Search results
Author(s):
Hugh Calkins
Added:
6 years ago
RE-CIRCUIT - Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation.
“At the American College of Cardiology congress, held in Washington D.C. in March this year, Dr Hugh Calkins (Professor of Cardiology and Director of the Electrophysiology Laboratory and Arrhythmia Service at the Johns Hopkins Hospital) presented the findings from Boehringer…
View more
Author(s):
George D Dangas
Added:
2 years ago
In this short video, Dr George Dangas (Mount Sinai Hospital, New York, NY, US) shares the findings from the ENVISAGE-TAVI AF hot line trial presented at ESC Congress 2021.
ENVISAGE-TAVI AF (Daiichi-Sankyo) compared the safety and efficacy of the DOAC edoxaban with VKAs (warfarin and its analogues) in atrial fibrillation patients with an indication for oral anticoagulation after successful TAVI.
…
View more
Author(s):
Yousif Ahmad
,
Gregory YH Lip
Added:
3 years ago
Atrial fibrillation (AF) leads to a prothrombotic state1 and places patients at risk of thromboembolic disease. The most common and serious complication of thromboembolism is stroke, and AF is held responsible for 25 % of all strokes.2 Strokes in the context of AF are associated with a higher mortality, longer hospital stay and lower levels of independence at discharge.3 These factors combine to…
View more
Author(s):
Oliver Plunkett
,
Gregory YH Lip
Added:
3 years ago
The introduction of novel oral anticoagulants (NOACs) has widened the treatment options for oral anticoagulation in stroke prevention in non-valvular atrial fibrillation (AF). Guidelines for the management of non-valvular AF have changed to reflect the emerging evidence of their relative safety and efficacy compared with warfarin (see Table 1).1–6
Download original
NOACs are now licensed for…
View more
Author(s):
Demosthenes G Katritsis
,
Bernard J Gersh
,
A John Camm
Added:
3 years ago
Thrombotic material in atrial fibrillation(AF) usually develops in the left atrial appendage as a result of decreased flow and stasis, possible endothelial dysfunction and a hypercoagulable state as indicated by increased fibrinogen, D-dimer, thromboglobulin and platelet factor 4 levels.1 In the Framingham Heart Study, the percentage of strokes attributable to AF increases steeply from 1.5 % in…
View more
Controversy Surrounding ROCKET-AF: A Call for Transparency, But Should We Be Changing Practice?
Author(s):
Jason D Matos
,
Peter J Zimetbaum
Added:
3 years ago
Article
Author(s):
Katrina Mountfort
,
A John Camm
,
Gregory YH Lip
,
et al
Added:
3 years ago
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is characterised by rapid and irregular heart rates. It is a lifethreatening condition present in up to 1.5 % of the population and accounts for approximately 15 % of all stroke events.1 While relatively unusual in those under 55 years, its incidence increases substantially with age, particularly between the ages of 65…
View more
Author(s):
Andreas Goette
,
Hein Heidbuchel
Added:
3 years ago
AF is the most common sustained cardiac arrhythmia and poses a significant public health challenge.1 In cases of AF, if sinus rhythm does not spontaneously return, cardioversion may be needed to alleviate symptoms and to improve cardiac performance.2 This may be performed by pharmacological methods, i.e. the administration of antiarrhythmic drugs, which is the preferred strategy in recent-onset…
View more
Author(s):
Marco Alings
Added:
3 years ago
Atrial Fibrillation(AF) is the most common cardiac arrhythmia, with the highest prevalence in elderly patients, and is characterised by an irregular heart rhythm that may result in clots in the heart that can spread throughout the circulatory system. It is seen in approximately 2 % of the European adult population and is a significant cause of increasing healthcare costs in developed countries.1…
View more
Author(s):
Pascal Vranckx
,
Marco Valgimigli
,
Hein Heidbuchel
Added:
3 years ago
Anticoagulation with vitamin K antagonists (VKAs) has been used for the long-term treatment and prevention of thromboembolic diseases and for stroke prevention in atrial fibrillation (AF) for the past half century. Until the last decade, VKAs were the only oral anticoagulant (OAC) agents available, and warfarin remains the most commonly prescribed OAC worldwide.1 Direct oral anticoagulants (DOACs…
View more